9 results about "Ganciclovir" patented technology

The invention relates to the technical field of medicine production, discloses a blocky raw material grinding device for triacetyl ganciclovir production, and solves the problems that an existing blocky raw material grinding device for triacetyl ganciclovir production is low in efficiency and high in energy consumption. Directional feeding is achieved through a special structure of a rotating pipe, the feeding accuracy is improved, low efficiency caused by uneven feeding is reduced, the pressure intensity is increased through eccentric rotation of a coarse grinding table and a convex ring, the crushing efficiency is improved, the coarse grinding time is shortened, and the energy consumption is reduced. According to linkage driving of a servo motor, the number of power sources is reduced, the structure is simplified, cost and maintenance difficulty are reduced, powder blanking is promoted through arc-shaped design of a drum plate, smooth material circulation is guaranteed, staying and blocking are reduced, small blocky raw materials are extruded in a linkage mode through an extrusion net, the suitability of fine grinding materials is improved, and the material blocking problem is reduced. The fine grinding quality and efficiency are guaranteed, and the overall energy consumption is reduced.

The invention belongs to the technical field of medicines, and particularly relates to compound tylosin ophthalmic gel as well as a preparation method and application thereof. The invention relates to compound tylosin ophthalmic gel. The compound tylosin ophthalmic gel is prepared from tylosin tartrate, ganciclovir, pharmaceutic adjuvants and water, the pharmaceutic adjuvants comprise a thickening agent, a filling agent, a solubilizer, a bacteriostatic agent and a pH regulator. The compound tylosin ophthalmic gel disclosed by the invention takes effect quickly, has a remarkable treatment effect on feline conjunctivitis, has a lasting curative effect, and can still keep a relatively good drug effect after drug withdrawal.

The present invention relates to human cytomegalovirus containing foreign antigens. Human cytomegalovirus vectors containing foreign antigens are disclosed. The vectors derived from TR strains are ganciclovir-sensitive, contain active US2, US3, US6, US7 and UL131A genes, and have deleterious or inactivating mutations in the UL82 gene that prevent pp71 expression.

The present application relates to catalyst and wastewater treatment technology, specifically relates to a catalyst of nitrogen-doped carbon nanotube coated cobalt, and a method for degrading antiviral drugs by activating peroxyacetic acid.The preparation method of the catalyst is as follows: a polyamide acid solution is uniformly mixed with a carbon nanotube dispersion solution, heated to reflux reaction, the solid after reaction is collected, the solid is dispersed in a cobalt salt solution, heated to 70-90 DEG C for stirring, so that cobalt is introduced into the solid, and the solid with introduced cobalt is pyrolyzed under inert atmosphere conditions, and the catalyst is obtained.The catalyst of nitrogen-doped carbon nanotube coated cobalt provided by the present application can not only efficiently degrade ACV, but also effectively degrade lamivudine, ganciclovir and favipiravir and other antiviral drugs.

The present invention relates to the field of virology. More specifically, the present invention provides methods and compositions useful for prevention and treatment of human cytomegalovirus (CMV). In one embodiment, a pharmaceutical composition comprises (a) emetine or a derivative thereof; (b) a human cytomegalovirus (HCMV) drug; and (c) a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition further comprises an adjuvant. In a specific embodiment, the HCMV drug is ganciclovir. In such embodiments, emetine is present at about 1 / 10 to about 1 / 100 the normal dosage for amebiasis.

The present application relates to a kind of hybridoma cell strains secreting monoclone antibody of ganciclovir and its application, belong to the field of immunodetection technique.The present application is by synthesizing ganciclovir hapten, preparation ganciclovir complete antigen and coating antigen, after cell fusion and screening, obtain ganciclovir monoclone antibody cell strain CLM-5D8, number is CGMCC NO.45924, preserved in China Microbial Culture Collection Center for General Microorganism.The hybridoma cell strain secretes ganciclovir monoclone antibody, has good detection sensitivity and detection specificity to ganciclovir, the IC 50 Value of ganciclovir is 2.03ng / mL, the cross reactivity of ganciclovir structural analog and functional analog is less than 1%, establishes solid foundation for ganciclovir immunological detection method, can be applied to the quantitative detection of ganciclovir.

The invention relates to the technical field of biological medicines, and particularly discloses application of an adeno-associated virus vector in preparation of a medicine for treating ovarian cancer. The adeno-associated virus vector comprises a modified AAV2 capsid and polynucleotide which is loaded in the modified AAV2 capsid and carries a therapeutic gene; wherein the EC1 targeting peptide is inserted into the amino terminal of the VP2 protein of the AAV2 capsid, and the VP1 protein has R585A and R588A mutations. Compared with a conventional virus vector, the vector can specifically target the ovarian cancer cells, efficient infection is achieved, the infection capacity of the vector on normal tissues such as the liver is remarkably reduced, and the vector has the advantage in the aspect of safety. In-vivo experiments show that by combining caudal vein injection of the adeno-associated virus vector carrying the HSV-TK with ganciclovir, tumor proliferation of mice with ovarian cancer transplanted tumors can be remarkably inhibited, and tissue organs such as liver and kidney of the mice are not obviously damaged.

The application belongs to the field of analysis and detection, and particularly relates to preparation of a bifunctional imprinting fluorescent probe and sensitive detection of marine biological toxins and antiviral drugs. The application adopts valganciclovir hydrochloride (VAL) similar in structure to saxitoxin (STX) as a pseudo-template, avoids the high toxicity of saxitoxin (STX) and the risk of template leakage, adopts a primary-secondary functional monomer synergistic strategy to construct a high-specificity recognition site, combines a fluorescent dye occupation-competition release mechanism to realize fluorescence signal transduction, and prepares an imprinting polymer fluorescent probe which has high selectivity, high sensitivity and fast response speed for STX and VAL, and can simultaneously adapt to the detection requirements of marine environmental samples and clinical biological samples, and still maintains excellent recovery rate and stability in a complex matrix.

This invention discloses a method for preparing a photothermal controlled-release hydrogel contact lens material. The method involves chemically bonding ganciclovir with hydroxypropyltrimethylammonium chloride chitosan, then adding methacrylic anhydride to introduce double bonds. The resulting product is used as a crosslinking agent to crosslink and copolymerize with hydroxyethyl methacrylate (MXene) nanosheets to prepare the hydrogel material. The prepared photothermal controlled-release hydrogel contact lens material can bond drugs to the polymer chains of the hydrogel contact lens for drug loading, avoiding drug loss due to tear rinsing, thereby improving drug storage stability. Furthermore, it can be modulated with near-infrared light to generate a photothermal effect, raising the hydrogel temperature and triggering the breakage of thermosensitive azo bonds, releasing the drug into the contact lens matrix. When the lens is worn, the drug can be slowly released from the contact lens into the eye, potentially making it a multifunctional contact lens material for treating eye diseases.